Astatine

Astatine is a chemical element with the symbol At and atomic number 85, classified as the heaviest of the halogens in Group 17 of the periodic table. It is a highly radioactive element of which no stable isotopes exist, and it holds the distinction of being the rarest naturally occurring element in the Earth's crust—so scarce that its total quantity at any given moment is commonly estimated at less than a single gram. Because bulk samples cannot be accumulated, nearly everything known about astatine's chemistry has been learned through ultratrace-scale experiments and theoretical calculation, making it one of the least characterized of all elements.

Background and Position in the Periodic Table

Astatine occupies period 6, directly below iodine in Group 17, alongside fluorine, chlorine, bromine, and iodine. Its predicted electron configuration, [Xe] 4f¹⁴ 5d¹⁰ 6s² 6p⁵, places seven valence electrons in its outermost shell, as expected for a halogen. Dmitri Mendeleev anticipated the existence of such an element as early as 1871, calling it "eka-iodine" and predicting several of its properties from periodic trends, including its higher density and atomic weight relative to iodine.

Despite its formal membership in the halogen family, astatine is widely regarded as transitional in character. Relativistic effects arising from its large nuclear charge diminish the metallic-to-nonmetallic trend observed among lighter halogens, and many computational studies predict that astatine would show metallic properties to a greater degree than iodine, possibly qualifying as a metalloid. Consequently, the element serves as a natural probe of the boundary between nonmetallic and metallic behavior at the lower edge of the periodic table.

History of Discovery

The identification of element 85 was marked by a series of erroneous claims. In 1931, Fred Allison of the Alabama Polytechnic Institute announced its discovery using a magneto-optical method and proposed the name "alabamine"; the method was later shown to be unreliable, and the claim was rejected. In the late 1930s, Horia Hulubei and Yvette Cauchois reported spectral evidence of the element and proposed the name "dor," a claim likewise not accepted. Further false reports in 1940 and 1942 proposed the names "helvetium" and "anglohelvetium."

Credit for the discovery belongs to Dale R. Corson, Kenneth Ross MacKenzie, and Emilio Segrè, who in 1940 at the University of California, Berkeley synthesized the element by bombarding bismuth-209 with alpha particles in a cyclotron, producing astatine-211. Because no isotope of the element was stable, they proposed the name "astatine," derived from the Greek astatos, meaning "unstable," combined with the "-ine" ending customary for halogens; the name was formally accepted in 1947. In 1943, Berta Karlik and Traude Bernert detected astatine occurring naturally in the decay chains of radium, establishing that the element exists in nature and completing the filling of Group 17 as then known.

Isotopes and Radioactivity

All isotopes of astatine are radioactive. More than thirty isotopes are known, spanning mass numbers from approximately 188 to 229, together with numerous nuclear isomers. The longest-lived are astatine-210, with a half-life of about 8.1 hours, and astatine-211, with a half-life of about 7.2 hours; no isotope persists longer than a single day.

Several isotopes occur in nature in vanishingly small quantities as short-lived intermediates in the radioactive decay chains of primordial uranium and thorium, most notably astatine-215 and astatine-219 in the actinium series (from uranium-235), astatine-218 in the uranium-238 series, and astatine-217 in the neptunium series. Astatine-211 has attracted particular interest because it decays partly by alpha-particle emission and partly by electron capture, the latter producing characteristic X-rays that allow the isotope to be imaged and its biodistribution quantified.

Physical Properties

Because astatine exists only in microscopic amounts that decay rapidly, its bulk physical properties have never been measured directly and remain matters of prediction. It is expected to be a dense, dark solid, with an estimated melting point near 302 °C and an estimated boiling point near 337 °C; its density has been estimated at roughly 6 to 7 grams per cubic centimeter. Its appearance has been conjectured to be black or metallic-looking, in line with its position as a heavy halogen.

Theoretical studies suggest that solid astatine would differ notably from iodine. Calculations of its properties indicate increased metallic character, and some investigators have proposed that condensed astatine might behave as a semiconductor or even exhibit metallic conduction, rather than forming the diatomic molecular solid characteristic of bromine and iodine. These predictions remain unverified for lack of a weighable sample.

Chemical Properties

Astatine's chemistry has been studied exclusively at ultratrace concentrations, typically involving quantities far below a microgram, where experiments rely on radiochemical detection. Despite these limitations, a substantial body of knowledge has accumulated. The best-characterized species in aqueous solution is the astatide anion, At⁻, formed by reduction, which behaves analogously to iodide and, like iodide, concentrates in the thyroid gland of animals. Zero-valent astatine is volatile and readily deposits on surfaces.

Astatine forms neutral interhalogen compounds with lighter halogens, including astatine iodide (AtI), astatine bromide (AtBr), and astatine chloride (AtCl), and compounds such as hydrogen astatide (HAt) and astatine cyanide have been reported or studied in trace amounts. In solution, oxidation produces oxyanions corresponding to higher oxidation states, including hypoastatite (AtO⁻), astatate (AtO₃⁻), and, under strongly oxidizing conditions, species attributed to the +7 state. Covalent bonding of astatine to carbon has been confirmed by direct measurement, and methods for attaching the atom to organic molecules—by electrophilic substitution, aryl iodonium intermediates, and boron-cluster chemistry—have been developed chiefly to support radiopharmaceutical research.

Occurrence and Rarity

Astatine is the rarest naturally occurring element on Earth. It exists in nature only as fleeting decay products within the uranium and thorium series, each atom surviving mere seconds to minutes before decaying further. Estimates of the total amount present in the Earth's crust at any instant vary with the decay-chain data assumed, but most calculations converge on a figure of no more than a few grams—frequently quoted as roughly one gram or less—for the entire planet. This extreme rarity arises from the combination of the short half-lives of natural astatine isotopes and the slow production rates within decay chains.

Production and Synthesis

Essentially all astatine used in research is artificially produced. The standard route to the medically important isotope astatine-211 bombards natural bismuth-209 targets with alpha particles of appropriate energy in a cyclotron, ejecting two neutrons. Alternative routes involve the decay of radon-211 generators. Production yields are small: individual irradiations typically furnish activities corresponding to microgram or sub-microgram quantities of the element, and worldwide annual production is measured in only small multiples of such amounts. Cyclotron facilities in North America, Europe, and Japan supply the isotope for preclinical and clinical research. Because astatine is volatile and adheres to surfaces, its handling, separation, and purification require specialized radiochemical techniques.

Applications and Research

Astatine has no applications outside scientific research, a direct consequence of its scarcity and radioactivity. Its principal contemporary significance lies in medicine, where astatine-211 is regarded as one of the most promising isotopes for targeted alpha-particle therapy. Its half-life of 7.2 hours is well matched to the pharmacokinetics of monoclonal antibodies, allowing the isotope to be conjugated to tumor-seeking proteins that deliver intense, short-range alpha radiation directly to cancer cells while sparing healthy tissue. The X-rays accompanying electron capture permit simultaneous imaging of the drug's distribution.

Preclinical studies have explored astatine-211-labeled antibodies and organic compounds against thyroid cancer, leukemia, lymphoma, melanoma, glioblastoma, and peritoneal carcinomatosis, and early-phase clinical trials have been conducted, most prominently in Japan. Because astatide mimics iodide, unbound astatine-211 has also been investigated for treating thyroid carcinoma as an analog of conventional radioiodine therapy.

Safety and Handling

As an alpha-emitting radionuclide that concentrates in the thyroid gland, astatine presents significant radiotoxicity hazards, and all work is conducted under strict radiological controls in specialized hot-cell and glovebox facilities. The intense local ionization produced by alpha decay makes even tracer quantities biologically potent, which is precisely the property exploited in therapy but also the source of risk in handling. No bulk quantities of astatine have ever existed, so conventional chemical hazards associated with a weighable sample remain hypothetical.

Scientific Significance

Beyond its potential medical value, astatine occupies an important place in fundamental science. It tests the limits of periodic trends: comparisons of astatine with iodine and tennessine illuminate how relativistic effects reshape chemical behavior among the heaviest elements. Its chemistry demonstrates the power of radiochemical "single-atom" techniques, whereby reaction thermodynamics and kinetics can be determined from quantities far below the threshold of conventional analysis. Historically, the element completed the halogen family as understood in the mid-twentieth century and confirmed Mendeleev's predictive framework; prospectively, it stands at the center of international efforts to bring alpha-emitting radiopharmaceuticals into routine clinical use.